Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study

Table 6 Major or nonmajor surgeries edoxaban interruption by renal function

	Pre- and postprocedure	Preprocedure only	Postprocedure only	No interruption	Total
Major surgery^a,b	160 (58.4)	47 (17.2)	13 (4.7)	54 (19.7)	274 (100)
CrCL ≤ 50	35 (54.7)	12 (18.8)	4 (6.3)	13 (20.3)	64 (100)
CrCL > 50	108 (57.4)	33 (17.6)	9 (4.8)	38 (20.2)	188 (100)
CrCL unknown	17 (77.3)	2 (9.1)	0	3 (13.6)	22 (100)
Nonmajor surgery^c	114 (22.3)	222 (43.4)	16 (3.1)	160 (31.3)	512 (100)
CrCL ≤ 50	26 (19.4)	54 (40.3)	3 (2.2)	51 (38.1)	134 (100)
CrCL > 50	71 (23.5)	137 (45.4)	9 (3.0)	85 (28.1)	302 (100)
CrCL unknown	17 (22.4)	31 (40.8)	4 (5.3)	24 (31.6)	76 (100)

Data are shown as n (%)^d
CrCL Creatinine clearance (mL/min), n Number of surgeries
^aMedian edoxaban interruption time for major surgeries, including surgeries without interruption, was 4.0 days
^bFor 2 surgeries, data for edoxaban use on the date of the surgery are unavailable
^cMedian edoxaban interruption time for nonmajor surgeries, including surgeries without interruption, was 1.0 days
^dPercentages are relative to the total number of surgeries in renal function subgroups

ISSN: 1477-9560